Genprex, Inc. - Common Stock (GNPX)

• Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes.

• Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes in New Video Presentation.

• Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes.

Working With World-Class Institutions and Collaborators to Provide Novel Treatment Approaches.

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating at two conferences during May. According to the announcement, Genprex CFO Ryan Confer will be presenting at the Sidoti Microcap Conference, which is held May 8–9, 2024. Confer’s presentation is slated to begin at 3:15 p.m. ET on May 8. The virtual presentation will include an overview of the company’s pioneering gene therapies for cancer and diabetes; Confer will also be available for virtual meetings with investors throughout the conference. An archived version of the presentation will be uploaded to the Genprex website. In addition, Genprex senior vice president of intellectual property and licensing Thomas Gallagher will be participating at the American Society of Gene & Cell Therapy Annual Meeting, which will be held in Baltimore on May 7–11, 2024. Gallagher will be available for in-person meetings with conference attendees throughout the five-day event.

Genprex (NASDAQGNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing Genprex’s non-viral Oncoprex(R) Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (“NSCLC”) in a humanized mouse model. “These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies,” said Rodney Varner, president, chairman and CEO at Genprex. “We believe this data could support the potential for a new drug candidate in our pipeline, and it also provides further evidence that the Oncoprex(R) Delivery System has the ability to be successful using genes other than the TUSC2 gene we are already using in clinical trials with Reqorsa(R).”

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock. Pricing was $4.215 per share of common stock (or prefunded warrant) and accompanying warrant, resulting in approximately $6.5 million before deducting typical fees and offering expenses. According to the announcement, the warrants have an exercise price of $4.09 per share and are exercisable on the date of issuance; they will expire five years following the date of issuance. Genprex plans to use the funds from this offering for working capital and general corporate purposes. In addition, the company amended certain existing warrants to purchase up to an aggregate of 194,248 shares of GNPX common stock that were previously issued to investors in March 2023 and July 2023. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock. Pricing was $4.215 per share of common stock (or prefunded warrant) and accompanying warrant, resulting in approximately $6.5 million before deducting typical fees and offering expenses. According to the announcement, the warrants have an exercise price of $4.09 per share and are exercisable on the date of issuance; they will expire five years following the date of issuance. Genprex plans to use the funds from this offering for working capital and general corporate purposes. In addition, the company amended certain existing warrants to purchase up to an aggregate of 194,248 shares of GNPX common stock that were previously issued to investors in March 2023 and July 2023. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Genprex (NASDAQGNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $4.09 per share, exercisable on the date of issuance and expiring five years following the date of issuance. Subject to customary conditions, the closing of the offering is expected to occur on or about March 21, 2024. The gross proceeds to Genprex are expected to be approximately $6.5 million, of which the company intends to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Genprex (NASDAQGNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $4.09 per share, exercisable on the date of issuance and expiring five years following the date of issuance. Subject to customary conditions, the closing of the offering is expected to occur on or about March 21, 2024. The gross proceeds to Genprex are expected to be approximately $6.5 million, of which the company intends to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has received a Notice of Patent Grant from the Korean Patent Office. The patent, which is effective through 2037, covers the use of the company’s lead drug candidate, Reqorsa(R) Immunogene Therapy, in combination with anti-PD-1 and PD-L1 antibodies. According to the announcement, this newest patent expands on previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to the company’s Acclaim-2 and Acclaim-3 clinical trials. Previous patents have been granted by authorized entities in the United States, Japan, Mexico, Russia, Australia, Chile and China. “We continue to secure exclusivity for our drug combinations of REQORSA with PD-1 antibodies, such as Keytruda(R), and PD-L1 antibodies, such as Tecentriq(R), for the treatment of cancer in some of the largest markets,” said Genprex senior vice president of intellectual property and licensing Thomas Gallagher in the press release. “It is important that we continue to add to our global intellectual property estate and to build protection around our drug combinations as we advance REQORSA through the clinic.”

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be presenting its research at next month’s 2024 American Association for Cancer Research Annual Meeting. The gathering is slated for April 5–10, 2024, and will be held in San Diego, California. According to the announcement, GNPX’s research collaborates will present positive preclinical data from studies of its lead product candidate, Reqorsa(R) Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy; both treatments use Genprex’s non-viral Oncoprex(R) Delivery System for the treatment of lung cancer. Three Genprex-supported posters are scheduled for presentation during the event. The first, titled “Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing Non-Small Cell Lung Carcinoma can induce cellular apoptosis,” is scheduled for presentation on April 7 from 1:30–5 p.m. PT. The second, titled “Tumor Suppressor Gene TUSC2 suppresses energy metabolism in lung cancer cells with opposite effects in normal bronchial epithelial cells,” is slated for April 8 from 1:30–5 p.m. PT. And the third, titled “Mechanism of NPRL2 gene therapy induced anti-tumor immunity in KRAS/STK11 MT aPD1 resistant metastatic NSCLC,” will be presented on April 8 from 9 a.m.–12:30 p.m. PT.

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications. According to the announcement, the company is expanding through sponsored research agreements and material transfer agreements with several academic research collaborators. The programs will be focused on studying TUSC2, the tumor suppressor gene used in Genprex’s lead drug candidate, REQORSA(R) (quaratusugene ozeplasmid), and NPRL2, another tumor suppressor gene. The company noted that new indications being evaluated include ALK-positive lung cancer as well as additional undisclosed programs. The expanded programs comprise research being conducted at the University of Michigan Rogel Cancer Center; Meharry Medical College in Nashville; and a major cancer research center in Houston. “We are developing a robust research program to expand the potential tumor targets, and even nontumor targets, that we may include in future clinical trials for REQORSA,” said Genprex chair, president and CEO Rodney Varner in the press release. “Research indicates that the TUSC2 gene used in REQORSA may benefit many types of cancers and potentially the treatment of other diseases. We are exploring opportunities to treat other cancers in which TUSC2 is often deleted or inactivated, and we are evaluating TUSC2 basic biology to better understand how to use our REQORSA treatment. Finally, we are also exploring the use of another tumor suppressor gene, NPRL2, in cancer treatment using our Oncoprex(R) Nanoparticle Delivery System.”

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications. According to the announcement, the company is expanding through sponsored research agreements and material transfer agreements with several academic research collaborators. The programs will be focused on studying TUSC2, the tumor suppressor gene used in Genprex’s lead drug candidate, REQORSA(R) (quaratusugene ozeplasmid), and NPRL2, another tumor suppressor gene. The company noted that new indications being evaluated include ALK-positive lung cancer as well as additional undisclosed programs. The expanded programs comprise research being conducted at the University of Michigan Rogel Cancer Center; Meharry Medical College in Nashville; and a major cancer research center in Houston. “We are developing a robust research program to expand the potential tumor targets, and even nontumor targets, that we may include in future clinical trials for REQORSA,” said Genprex chair, president and CEO Rodney Varner in the press release. “Research indicates that the TUSC2 gene used in REQORSA may benefit many types of cancers and potentially the treatment of other diseases. We are exploring opportunities to treat other cancers in which TUSC2 is often deleted or inactivated, and we are evaluating TUSC2 basic biology to better understand how to use our REQORSA treatment. Finally, we are also exploring the use of another tumor suppressor gene, NPRL2, in cancer treatment using our Oncoprex(R) Nanoparticle Delivery System.”

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His presentation, which will begin at 1:30 p.m. ET on Feb. 26, will include an overview of the company’s gene therapies for cancer and diabetes; Confer will also be available for in-person, one-on-one meetings with investors through the conference platform.

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex’s proprietary lead product candidate with AstraZeneca’s Tagrisso(R) to treat patients with late-stage non-small cell lung cancer (“NSCLC”). An open-label, multicenter phase 1/2 clinical trial, the Accliam-1 trial has completed its phase 1 component and is moving on to phase 2. The company anticipates enrolling an estimated 66 patients in phase 2a, with one-half of the study participants receiving Tagrisso treatment alone and the other half receiving Tagrisso treatment and chemotherapy; the study will determine toxicity profiles of patients with different eligibility criteria, as well as efficacy and other endpoints.

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase 2a expansion portion of its Acclaim-1 clinical study of Reqorsa(R) therapy (quaratusugene ozeplasmid). The study combines Genprex’s proprietary lead product candidate with AstraZeneca’s Tagrisso(R) to treat patients with late-stage non-small cell lung cancer (“NSCLC”). An open-label, multicenter phase 1/2 clinical trial, the Accliam-1 trial has completed its phase 1 component and is moving on to phase 2. The company anticipates enrolling an estimated 66 patients in phase 2a, with one-half of the study participants receiving Tagrisso treatment alone and the other half receiving Tagrisso treatment and chemotherapy; the study will determine toxicity profiles of patients with different eligibility criteria, as well as efficacy and other endpoints.

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was granted orphan drug designation (“ODD”) by the US Food and Drug Administration (“FDA”) for its REQORSA(R) immunogene therapy for the combination of its immunogene therapy REQORSA(R) and Genentech Inc.’s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer (“SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment earlier this year .

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general counsel and chief strategy officer, will be providing an overview of the company’s gene therapies for cancer and diabetes at the upcoming BIO-Europe 2023 Conference taking place in Munich, Germany. Vaczy’s presentation is slated to begin at 4:45 p.m UTC on Tuesday, Nov. 7, 2023. Several members of Genprex’s executive leadership team will be in attendance at BIO-Europe 2023. Those interested in meeting Genprex management during the event should request a meeting through the conference portal or reach out to investor relations at investors@genprex.com .

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is hosting an upcoming virtual key opinion leader (“KOL”); the event will focus on the current state of lung cancer treatments and the challenges facing patients. Titled “Bringing Gene Therapy to the Fight Against Lung Cancer,” the event is slated for Oct. 27, 2023, at 12:30 p.m. ET. During the event, Alexander I. Spira, MD, PhD, FACP, and director of the Virginia Cancer Specialists (VCS) Research Institute and the phase I trial program at Johns Hopkins Hospital will join Daniel Morgensztern, MD, a professor of medicine and the director of thoracic oncology at Washington University School of Medicine; both doctors are medical oncologists.

Genprex (NASDAQGNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical and preclinical data at the prestigious 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15 at the Hynes Convention Center in Boston.

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQGNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

Genprex (NASDAQGNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced its entry into an exclusive license agreement related to a particular gene therapy for both type 1 and type 2 diabetes. “Specifically, the announcement involves a worldwide exclusive license to a patent application and related technology, and a worldwide non-exclusive license to use certain related know-how using the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter, as developed by the University of Pittsburgh. Genprex is developing technologies to administer disease-fighting genes that will provide new therapies in the fight against cancer and diabetes for large patient populations. In regard to the company’s diabetes approach, the Pdx1 and MafA genes are delivered directly to the pancreas through a novel infusion process (gene therapy candidates ‘GPX-002’ and ‘GPX-003’),” a recent article reads. “We are continuing to build a fortress of protection and a powerful intellectual property portfolio for our diabetes gene therapy program,” Genprex chairman, president and CEO Rodney Varner is quoted as saying. “The addition of this license to MafB promoter technology expands and strengthens the potential for this novel gene therapy to treat type 1 and type 2 diabetes.”

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (“ODD”) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQGNPX) ( Profile ) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (“SCLC”). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.’s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC NASDAQ: JAZZNASDAQJAZZ)(NASDAQ: ALXONASDAQALXO and Achilles Therapeutics PLC (NASDAQ: ACHLNASDAQ) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

EQNX::TICKER_START (NASDAQGNPX),(OTCQX:RHHBY),NASDAQ:JAZZNASDAQJAZZ)(NASDAQ:ALXONASDAQALXO,(NASDAQ:ACHLNASDAQ) EQNX::TICKER_END